

**Sareum Holdings plc**

("Sareum" or the "Company")

**Appointment of Joint Broker**

**Cambridge, UK, 18 December 2024** -Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, is pleased to announce the appointment of Oberon Capital as a Joint Corporate Broker with immediate effect. Oberon Capital is a trading name of Oberon Investments Limited.

Strand Hanson Limited and Hybridan LLP will continue to act as the Company's Nominated Adviser and Joint Corporate Broker, respectively.

- Ends -

**For further information, please contact:**

**Sareum Holdings plc**

Stephen Parker, Executive Chairman

01223 497700  
ir@sareum.co.uk

**Strand Hanson Limited (Nominated Adviser)**

James Dance / James Bellman

020 7409 3494

**Oberon Capital (Joint Broker)**

Mike Seabrook / Nick Lovering

020 3179 5300

**Hybridan LLP (Joint Broker)**

Claire Noyce

020 3764 2341

**ICR Healthcare (Financial PR)**

Jessica Hodgson / Davide Salvi / Kumail Waljee

0203 709 5700

**About Sareum**

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has completed Phase 1 clinical development and is readying for phase 2 trials.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at [www.sareum.com](http://www.sareum.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

APPFZMMZNNDGDZM